These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
287 related articles for article (PubMed ID: 32378398)
1. Chronic spontaneous urticaria treated with omalizumab: what differentiates early from late responders? Asero R Eur Ann Allergy Clin Immunol; 2021 Jan; 53(1):47-48. PubMed ID: 32378398 [No Abstract] [Full Text] [Related]
2. Anti-TPO IgG/Total IgE Ratio: Biomarker for Omalizumab Response Prediction in Chronic Spontaneous Urticaria. Brás R; Esteves Caldeira L; Bernardino A; Costa C Int Arch Allergy Immunol; 2023; 184(9):866-869. PubMed ID: 37557083 [TBL] [Abstract][Full Text] [Related]
3. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria. Skander D; Allenova A; Maurer M; Kolkhir P Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030 [No Abstract] [Full Text] [Related]
6. A case of chronic spontaneous urticaria unresponsive to ligelizumab successfully treated with omalizumab. Russo F; Cortonesi G; Lazzeri L; Taddeucci P; Rubegni P Dermatol Ther; 2022 Nov; 35(11):e15859. PubMed ID: 36164841 [No Abstract] [Full Text] [Related]
7. Omalizumab re-treatment rates in chronic spontaneous urticaria. Khan S; Sholtysek S Eur Ann Allergy Clin Immunol; 2020 May; 52(4):187-189. PubMed ID: 32378397 [No Abstract] [Full Text] [Related]
8. Combined treatment with omalizumab and secukinumab in a patient with chronic spontaneous urticaria and psoriasis. Karstarli Bakay OS; Kacar N Dermatol Ther; 2022 Sep; 35(9):e15638. PubMed ID: 35703106 [No Abstract] [Full Text] [Related]
9. Omalizumab in severe chronic urticaria: are slow and non-responders different? Asero R Eur Ann Allergy Clin Immunol; 2021 Nov; 53(6):263-266. PubMed ID: 32914943 [No Abstract] [Full Text] [Related]
10. Validation of UAS7 among children with chronic spontaneous urticaria. Gabrielli S; Mulé P; Prosty C; Gooding G; Le M; Zhang L; Netchiporouk E; Baum S; Greenberger S; Ensina LF; Lovett A; Zhang X; Ben-Shoshan M J Allergy Clin Immunol Pract; 2022 Jul; 10(7):1927-1929.e1. PubMed ID: 35272072 [No Abstract] [Full Text] [Related]
11. Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria. Pedersen NH; Sørensen JA; Ghazanfar MN; Zhang DG; Vestergaard C; Thomsen SF Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511088 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug. Asero R Allergy; 2018 Nov; 73(11):2242-2244. PubMed ID: 29989179 [No Abstract] [Full Text] [Related]
13. IgE and D-dimer baseline levels are higher in responders than nonresponders to omalizumab in chronic spontaneous urticaria. Cugno M; Genovese G; Ferrucci S; Casazza G; Asero R; Marzano AV Br J Dermatol; 2018 Sep; 179(3):776-777. PubMed ID: 29582427 [No Abstract] [Full Text] [Related]
14. The Crucial Role of IgE as a Predictor of Treatment Response to Omalizumab in Chronic Spontaneous Urticaria. Maurer M; Kolkhir P; Moñino-Romero S; Metz M J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2390-2391. PubMed ID: 37364668 [No Abstract] [Full Text] [Related]
15. Efficacy of additional treatment for chronic spontaneous urticaria refractory to treatment - A single-center retrospective real-world study. Ohata M; Oda Y; Washio K; Fukunaga A; Nishigori C J Dermatol; 2022 Jan; 49(1):e7-e8. PubMed ID: 34632611 [No Abstract] [Full Text] [Related]
16. [HOW PERIPHERAL BASOPHILS IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA ARE CHANGED WITH OMALIZUMAB TREATMENT?]. Oda Y; Washio K; Mizuno M; Imamura S; Nishigori C; Fukunaga A Arerugi; 2021; 70(9):1196-1199. PubMed ID: 34759084 [No Abstract] [Full Text] [Related]
17. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):T88-T90. PubMed ID: 37871896 [No Abstract] [Full Text] [Related]
18. Indication of Omalizumab for Chronic Urticaria Using the 'Urticaria Control Test' Instead of 'Urticaria Activity Score': Possible Impact for Health Systems. Sánchez J; Alvarez L; López JF Actas Dermosifiliogr; 2024 Jan; 115(1):88-90. PubMed ID: 36754254 [No Abstract] [Full Text] [Related]
19. Selective IgE Deficiency Predicts Poor or No Response of Chronic Spontaneous Urticaria to Omalizumab. Picado C; Mascaró JJ; Vlagea A; Pascal M; Muñoz-Cano R; Bartra J J Investig Allergol Clin Immunol; 2022 Dec; 32(6):504-506. PubMed ID: 35225792 [No Abstract] [Full Text] [Related]
20. High-dose omalizumab use in patients with chronic spontaneous urticaria. Alizadeh Aghdam M; van den Broek F; Rijken F; Knulst AC; Röckmann H J Allergy Clin Immunol Pract; 2020 Apr; 8(4):1426-1427.e1. PubMed ID: 31678293 [No Abstract] [Full Text] [Related] [Next] [New Search]